Login

Journal Front Page

News & Events

  • April 2024 Issue delayed
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, Volume 13, Issue 2 (April 2024) Issue) schedule published on 15 April 2024 is delay due to some technical problem. It will published on 22 April 2024. Sorry for inconvenience. For other details You can vist the website http://www.ajper.com
  • Call for article for April 2024 issue
    • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 March, 2024 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • January 2024 Issue published
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 13, Issue 1 (January 2024) Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
    • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
    • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
    • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

Enhancement of Oral Bioavaibility of Irbesartan by Niosomal Formulation

Niharika Thakur1, Piush Khare1, Azad Khan2, Amit Kumar Srivastava*3

1Truba Institute of Pharmacy, Bhopal, (M.P.), India.

2ITS Paramedical (Pharmacy) College, Muradnagar Ghaziabad, (U.P.), India.

3Sapience Bioanalytical Research Lab, Bhopal, (M.P.), India.

ABSTRACT

The purpose of this research was to prepare the Irbesartan niosome in a trial to improve its oral bioavaibility. Niosome are vesicles mainly consisting of nonionic surfactant. These NSVs were prepared by the conventional film hydration method. The mixture consisted of cholesterol, span-80 & chloroform in the molar ratio 65:60:5 respectively. The entrapment ~10% of Irbesartan used in the hydration, for hydration phosphate buffer pH 7.5 solution was used, the vesicles have an average size of 0.95m, the most probable size of 0.8m and average size range 0.4 to 2.2 m, most of the noisome have unilamellar or spherical shape. The niosomal formulation significantly retard release compared with free drug. The in-vivo study revealed that niosomal dispersion significantly improved oral bioavaibility of Irbesartan in rabbit, after a single oral dose of 40mg/kg. The average relation bioavaibility of the drug from the niosomal dispersion in relation to the free solution was 2.55 indicating more than two folds increase in drug bioavaibility. In conclusion, the niosomal formulation would be an improving delivery system for Irbesartan, with improved bioavaibility and prolonged drug release profiles.

Keywords: Niosome, Oral bioavaibility, Irbesartan.


[Full Text Article]